StemCell Therapy

Blue Biotechnology Market Forecast 2020-2026

The Global Blue Biotechnology Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.

The report consists of trends that are anticipated to impact the growth of the Blue Biotechnology Market during the forecast period between 2020 and 2026. Evaluation of these trends is included in the report, along with their product innovations.

Get a PDF Copy of the Sample Report for free @ https://industrygrowthinsights.com/request-sample/?reportId=136719

The Report Covers the Following Companies:Aker BioMarineMarinovaNew England BiolabsPML ApplicationsSea Run HoldingsPICESDonald Danforth Plant Science CenterShell Marine ProductsGeoMarine BiotechnologiesGlycoMarCellgen BiologicalsNurture Aqua TechnologySamudra BiopharmaSanosil Biotech

By Types:EnzymesPharma ProductsBulk ChemicalsBiopolymers

By Applications:Bio-EngineeringGenomicsVaccine DevelopmentDrug DiscoveryOthers

Furthermore, the report includes growth rate of the global market, consumption tables, facts, figures, and statistics of key segments.

By Regions:

Grab Your Report at an Impressive Discount! Please click here @ https://industrygrowthinsights.com/ask-for-discount/?reportId=136719

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2026

Important Facts about Blue Biotechnology Market Report:

What Our Report Offers:

Make an Inquiry of This Report @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=136719

About Industrygrowthinsights:Industrygrowthinsights has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://Industrygrowthinsights.com

Continue reading here:
Blue Biotechnology Market Size, Share & Trends Analysis Report By Product Types, And Applications Forecast To 2026 - Jewish Life News

1.5 Present and future trends in biotechnology

During the twentieth century humankind has harnessed microorganisms to produce useful biochemical including antibiotics, vitamins, amino acids, flavors and colors, as well as specific proteins (Carlier 2001). Some of these proteins have important medical uses such as insulin, human growth hormone and blood factors like erythropoietin. In fact, manufacturers have developed a series of proven, safe, microbial hosts for use in the production of several enzymes (Warke and Chandratre 2003). Further, enzymes that have not been readily available in adequate quantity can be produced using technology. This in turn has opened up important applications beneficial to humankind. Additionally, modern techniques are leading to the development of tailored enzymes with optimized functional properties specific for their intended use. An example of this is the modification in specific proteases so that they work more efficiently in the alkaline environment of detergent formulations. As a result, less of the modified protease is needed to deliver equivalent cleaning power, while using fewer resources during the manufacturing process.

The microbial cell, a bacterium, yeast, or mold, is the key instrument in many enzyme production processes. To optimize the microbial strains for production of the desired enzyme, the strains genetic properties are often modified either through natural evolution or through classical breeding and selection techniques; these classical techniques have been used for decades to improve microbial production strains. The precise methods of genetic modification have been developed. The methods, sometimes termed genetic engineering, are based on processes occurring in nature - the transfer of genes between different cells.

Scientists to transfer genetic material between cells from the same or different species, microorganisms such as yeasts, molds and bacteria with new or improved properties for industrial applications can be developed. In nature, genetic modification has been occurring since life began. Such genetic changes are generally random, with a natural selection process favoring the changes best adapted for survival. Using this process, animal, plant and microbial breeders have likewise selected individuals within a species with desired characteristics for further propagation.

Using the tools of modern biotechnology, modifications can now be made more precisely and with much less chance of developing unwanted secondary changes that could potentially have undesired effects. In nature and in our production systems, microbes do not express only single enzymes. Rather, each microbial cell has the genetic nature to produce many different enzymes. Frequently, only one of these enzyme activities is needed for a specific application and the side activities are removed or substantially reduced during the recovery process. Often, these side activities are unwanted and may even be detrimental to the final use. Additionally, scientists are now able to discover and/or evolve enzymes that will catalyze pure compounds for applications including textile wet processing such as enzymatic desizing with alpha amylase, bioscouring with pectinase, protease, lipase and cellulase enzymes, binary and mixed enzymatic system, and biopolishing with cellulase enzymes, lipase enzyme for improving hydrophilic nature of polyester fibre both greatly reducing unwanted byproduct production as well as making the target product potentially safer and more effective (Buschie-Diller et al 1994).

Modern biotechnology is one tool that can help meet the challenge this growth poses and also contributed to (a) ecofriendly environment (b) safety and health, (c) reduced water demand in manufacturing processes, (e) reduced industrial waste and (f) aided in pollution remediation. Enzymes produced using modern biotechnology contributes to this effort by assuring the availability of safe, pure enzymes that replace harsh chemical processes (reducing energy consumption and environmental burden). Modern tools of biotechnology, enzymes from nature can be accessed which are sufficiently robust to be useful at extremes of pH and temperature and thus hold great promise for replacing certain chemical processes with much cleaner protein-catalyzed processes (Gubitz and Cavaco-Paulo 2001). Just as exciting, these new enzymes can make the dream of converting waste biomass to useful energy an economic reality. Overall, the use of modern biotechnology for enzyme production can have a major impact on improving the cost and quality of products at the same time working towards sustainability.

Enzymes have applications in many fields, including organic synthesis, clinical analysis, textile processes, and finishing, pharmaceuticals, detergents, food production and fermentation. The application of enzymes to organic synthesis is currently attracting more and more attention. The discovery of new microbial enzymes through extensive and persistent screening will open new, simple routes for synthetic processes and consequently, new ways to solve environmental problems (Calafell et al 2005).

Research on enzyme systems for textile processing and finishing has mainly focused on amylases and cellulases. However, recent biotechnology and genetic engineering advances have opened opportunities for successful applications of other enzyme systems, such as lipases, xylanases, laccases, proteases and pectinases (Emilla Csiszar et al 1998). Today, enzymes can be customized for specific target areas; for example, enzymatic degumming of silk, bioscouring of cotton textiles and antifelting and softening of wool. The basic mechanisms involving enzyme systems and interactions with textile substrates are likely noticed. Using several enzyme systems and application conditions, few researchers are being involved in studying the fibre/enzyme interactions and the compatibility of enzymes in combination (Gisela Buschle-Diller, and S. Haig Zeronian 1998).

Biotechnology offers an increasing potential for the production of goods to meet various human needs. In enzyme technology, a subfield of biotechnology, new processes have been and are being developed to manufacture both bulk and high value added products utilizing enzymes as biocatalysts (Tzanko et al 2002). Enzymes are also used to provide services, as in washing and environmental processes, or for analytical and diagnostic purposes. The driving force in the development of enzyme technology, both in academia and industry, has been and will continue to be:

The development of new and better products, processes and services to meet these needs; and/or

The improvement of processes to produce existing products from new raw materials as biomass.

Enzymes from nature can be accessed which are sufficiently robust to be useful at extremes of pH and temperature and thus hold great promise for replacing certain chemical processes with much cleaner protein-catalyzed processes (Csiszar et al 2001). These new enzymes can make the dream of converting waste biomass to useful energy an economic reality. Overall, the use of modern biotechnology for enzyme production can have a major impact on improving the cost and quality of products at the same time working towards sustainability.

Read the original:
Biotechnology - an overview | ScienceDirect Topics

An RIT alumnus is helping to lead Bolivias response to the COVID-19 pandemic.

Mohammed Mostajo-Radji 11 (biotechnology) was appointed as Bolivias first ambassador for science, technology and innovation in February. He is typically based out of Silicon Valley, helping to encourage technology investment in Bolivia and facilitating exchanges between universities, technology companies, startups, and more.

But on March 19 he flew back home at the request of Bolivias interim president, Jeanine ez, to help coordinate his countrys efforts to combat COVID-19s spread. His country faces many challenges in fighting the virus, including one of the worlds worst healthcare systems and a unique geographic predicament.

Our countrys high altitude is by far our biggest challenge right now because most of the ventilators dont work appropriately at this level, said Mostajo-Radji. We have large populations living at altitudes above 13,000 feet and most ventilators are made and tested at sea level. In the current market its already extremely difficult to get a ventilator, but maybe only 30 percent of them actually work here.

But he is uniquely equipped to handle the rigors of the job. While at RIT, Mostajo-Radji developed an interest in science diplomacy, minoring in science, technology and society. For his senior thesis, he conducted experiments using Real-time polymerase chain reaction, the same equipment that is now commonly used to test for COVID-19. As he travels around Bolivia helping to set up testing labs, his experience with the equipment allows him to test a few samples to ensure everything is working properly.

After earning his degree at RIT, he went on to earn his Ph.D. in cellular and molecular biology at Harvard University in 2017 and is currently also a postdoctoral scholar in regeneration medicine at University of California, San Francisco.

Mostajo-Radji said he is proud to serve in this capacity and enjoys the work, but when looking back he is shocked at how quickly everything has escalated.

If you had asked me six months ago if I would have been doing this, I would have laughed, he said.

Read the original:
RIT Rallies: Biotechnology alumnus helping Bolivia respond to COVID-19 pandemic | College of Science - RIT University News Services

The S&P 500 is hitting its low point of the day as the FAANG names have reversed lower and breadth runs negative. There isn't any major rush for the exits but the momentum is more concentrated on some of the "economic reopening" plays such as the airlines and Boeing (BA) . Small-cap speculation has slowed and the Russell 2000 ETF (IWM) is struggling.

It isn't just the bears that would welcome a pullback in this market, many bulls would like some better entry points and weakness to buy. Chasing stocks higher day after day grows tiresome when you still have idle cash to put to work. Trying to stay in tune with a market that seems to be acting without regard to the news flow so often is quite exhausting.

While I'm not anticipating any major market pullback, I am looking for some signs that we may have some brief corrective action. At the top of my list is an intraday reversal and a poor close. We have the intraday reversal Thursday but it is fairly mild and we have to wait to see if there is any acceleration of selling into the close.

Even with that sort of action, it is going to be tough for the bears to gain downside traction, especially since bad news doesn't seem to produce any negative response. We have a long list of negative developments to explain some downside action but we just haven't had any come to fruition.

One the strategies I'm developing right now is to slowly start to build some longer term positions in a few biotechnology names as the pullback developes. This remains one of my favorite groups as it is relatively insulated from the ongoing coronavirus sector.

Four biotechnology names I'm looking to buy on weakness are Personalis (PSNL) , Ocular Therapeutix (OCUL) , Aurinia Pharmaceuticals (AUPH) (one of my stock picks for 2020) and Baduax Bio (BXRX) .

I don't see any rush to load up on these names but I'll be watching to make some smaller buys as the market action develops.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

See the article here:
4 Biotechnology Stocks I'm Buying on Weakness - RealMoney - TheStreet

ALAMEDA, Calif. & FARMINGTON, Conn.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and ImStem Biotechnology, Inc., a biopharmaceutical company developing human embryonic stem cell-derived mesenchymal stem cells (hES-MSC), today announced their signing of a non-binding letter of intent for ImStem to obtain from AgeX a non-exclusive license to use AgeXs embryonic stem cell line ESI 053 to derive ImStems investigational MSC product IMS001 for development in COVID-19 as well as acute respiratory distress syndrome (ARDS) due to other causes. AgeX and ImStem are co-operating to finalize financial terms and other provisions of a license agreement.

ImStem has previously used AgeX ESI 053 to derive the ImStem IMS001 product which is being investigated for multiple sclerosis under an IND. Earlier this year, the U.S. Food and Drug Administration (FDA) cleared IMS001 to begin a Phase 1 clinical study in patients with multiple sclerosis, after a clinical hold on its Investigational New Drug (IND) application was removed. This is believed to be the first MSC product derived from human embryonic stem cells to be accepted for a clinical trial by the FDA. AgeX and ImStem already have a commercial license in place, which grants ImStem rights to use AgeXs ESI 053 to derive IMS001 as a product candidate for development in autoimmune disease, including multiple sclerosis.

To date, in patients with pneumonia and ARDS due to COVID-19, preliminary literature suggests MSCs, such as ImStems hES-MSC candidate IMS001, may warrant further development consideration. An early clinical study conducted in China by an unrelated group with a different MSC product, Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia, and published in Aging and Disease (2020, Vol. 11, No. 2, pp. 216-228) showed that an intravenous infusion of a different MSC product appeared safe and improved functional outcomes in seven treated patients with COVID-19 pneumonia. MSCs are well recognized to be immunomodulatory in nature, possessing immunosuppressive and anti-inflammatory properties.

Even before their application to COVID-19, MSCs were being investigated as a potential therapeutic option in ARDS, and emerging data in preclinical models has been encouraging. ARDS remains an area of considerable unmet medical need, affecting around 200,000 patients annually in the U.S., accounting for 10% of all intensive care unit patients, and having a mortality of approximately 40%. At the present time, no specific direct therapies exist for ARDS and only supportive treatment is available.

We feel privileged to be part of a global effort to combat COVID-19. This is a unique opportunity for AgeX to leverage its resources to help with the public health challenge at hand. Decades of pioneering work with human embryonic stem cells means this technology is now at a point where it may play a role in the development of a cell-based approach to combating COVID-19. We are very excited by the prospect of expanding our relationship with ImStem to include COVID-19 and ARDS, said Dr. Nafees Malik, Chief Operating Officer of AgeX.

We welcome the opportunity to continue to collaborate with AgeX and explore future development of our IMS001 product in COVID-19 and ARDS from other causes, commented Richard Kim, M.D., Chief Medical Officer of ImStem Biotechnology.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. AgeXs PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeXs core product pipeline is intended to extend human healthspan. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

About ImStem Biotechnology

ImStem Biotechnology, Inc. is aspiring to revolutionize how serious diseases with significant unmet needs are treated with a new generation of regenerative and cellular therapies. Pioneering research by its current founder and Chief Technology Officer Dr. Xiaofang Wang and Dr. Ren-He Xu, former director of UConn Stem Cell Institute, led to the proprietary state-of-the-art pluripotent stem cell technology, enabling off-the-shelf, allogeneic stem cell-derived products to be manufactured in scale, differentiating itself from the typical challenges imposed by autologous adult cell therapy products. The company's mission is to advance the science and understanding of human pluripotent stem cell based regenerative cellular therapies through novel and creative development pathways and to fulfill unmet medical needs in serious diseases. And its development strategy focuses on neurologic, autoimmune, degenerative, and rare orphan diseases. ImStem Biotechnology Inc. is a privately held company headquartered in Farmington, CT.

For more information, visit http://www.imstem.com.

Forward-Looking Statements for AgeX

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. In addition, with respect to AgeXs letter of intent with ImStem there is no assurance that (i) AgeX and ImStem will successfully conclude negotiations and enter into a license agreement; (ii) ImStem will be successful in developing any therapeutic products from a stem cell line licensed by AgeX or that any therapeutic product that may be developed will receive FDA or foreign regulatory approval, or (iii) AgeX will derive revenue or other financial benefits from any license agreement that might be signed with ImStem. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Link:
AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other...

');},success: function(response) {$('.megamenuthird[data-menu=' + $data_megamenu + '-articles]').html(response);},error: function(xhr) { // if error occured$('.megamenuthird[data-menu=' + $data_megamenu + '-articles]').html("Error occured.please try again"); }});}}//Child Level Menu Hoverfunction get_childlevelmenu(currentid){//console.log('current id '+currentid);var $currentelement = $('#'+currentid);$('.menu-item-'+$('#'+currentid).closest('.themegamenu').attr('cid').split('-')[3]).removeClass('defaultajax-1');var $data_menu = $('#'+currentid).closest('li').data('menu');var ajaxreplaceContent = $('#'+currentid).closest('.themegamenu').data('megamenu')+'-articles';var submenu = $data_menu.split('-');var data_menu_class=submenu[0];//$('.megamenuthird').empty();$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').empty();$('li.level_2').removeClass('activeli');$currentelement.closest('li').siblings().removeClass('activeli');$currentelement.closest('li').addClass('activeli');var current_megamenu_second = $('.megamenusecond[data-menu='+$data_menu+']').length;$('.megamenuopen .megamenusecond').removeClass('megamenusecond-show');//$currentelement.closest('li').find('.megamenuopen .megamenusecond').removeClass('megamenusecond-show');$('.megamenusecond[data-menu=' + $data_menu + ']').addClass('megamenusecond-show');//if(current_megamenu_seconda').html();/********* End level3 checking menu ********/// checking 4th level menu /*** 4th level Objec code here **///getting parent data-menuvar levelfour_data_menu = $('.megamenusecond[data-menu='+$data_menu+']').find('li.level_3.activeli').data('menu');// End getting parent data-menuvar subofSubChildLevel_cat_id = $('.megamenusecond[data-menu='+levelfour_data_menu+']').find('li.level_4.activeli').data('cat');var subofSubChildLevel_data_menu = $('.megamenusecond[data-menu='+levelfour_data_menu+']').find('li.level_4.activeli').data('menu');var subofSubChildLevel_taxnomy_type= $('.megamenusecond[data-menu='+levelfour_data_menu+']').find('li.level_4.activeli').data('type');var subofSubChildLevel_title = $('.megamenusecond[data-menu='+levelfour_data_menu+']').find('li.level_4.activeli>a').html();if(subofSubChildLevel_title!=''){var ajx_title=subofSubChildLevel_title;}else{var ajx_title=subChildLevel_title;}/*** End 4th level Objec code here **/if(subofSubChildLevel_cat_id!=''){var data_obj ={'title':ajx_title,'subofSubChildLevel_cat_id':subofSubChildLevel_cat_id,'subofSubChildLevel_taxnomy_type':subofSubChildLevel_taxnomy_type,'subChildLevel_cat_id': subChildLevel_cat_id,'subChildLevel_taxnomy_type' :subChildLevel_taxnomy_type,'ChildLevel_data_type':ChildLevel_data_type,'ChildLevel_data_cat_id':ChildLevel_data_cat_id,'parent_data_cat_id':parent_data_cat_id,'parent_data_type':parent_data_type};}else{var data_obj ={'title':ajx_title,'subChildLevel_cat_id': subChildLevel_cat_id,'subChildLevel_taxnomy_type' :subChildLevel_taxnomy_type,'ChildLevel_data_type':ChildLevel_data_type,'ChildLevel_data_cat_id':ChildLevel_data_cat_id,'parent_data_cat_id':parent_data_cat_id,'parent_data_type':parent_data_type};}} if( ajaxRequestProject != null ) {ajaxRequestProject.abort();ajaxRequestProject = null;}ajaxRequestProject = $.ajax({type: 'POST',url: 'https://pharmaceutical-business-review.com/wp-admin/admin-ajax.php?action=mega_posts',data: data_obj, dataType: "html",beforeSend: function() {$('.megamenuthird[data-menu=' + ajaxreplaceContent+ ']').html('');},success: function(response) {$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html(response);},error: function(xhr) { // if error occured$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html("Error occured.please try again");}});}//Subchild Level Menu Hover//Child Level Menu Hoverfunction get_subchildlevelmenu(currentid){var $currentelement = $('#'+currentid);$('.menu-item-'+$('#'+currentid).closest('.themegamenu').attr('cid').split('-')[3]).removeClass('defaultajax-1');var $data_menu = $currentelement.closest('li').attr('data-menu'); var submenu = $data_menu.split('-'); var data_menu_class=submenu[0];var ajaxreplaceContent = $('#'+currentid).closest('.themegamenu').data('megamenu')+'-articles';$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').empty();$('.megamenuthird').removeClass('megamenuthird-show');$('.megamenuthird[data-menu=' + $data_menu + ']').addClass('megamenuthird-show');$('li.level_3').removeClass('activeli');$currentelement.closest('li').addClass('activeli');var subChildLevel_title = $currentelement.html();//last child level$currentelement.closest('li').parent().closest('li').find('.megamenusecond-new[data-menu=' + $data_menu + ']').find('li.level_4').removeClass('activeli');var $data_menu = $('#'+currentid).closest('li').data('menu');$('.megamenuopen .megamenusecond-new').removeClass('megamenusecond-show');$currentelement.closest('li').parent().closest('li').find('.megamenusecond-new[data-menu=' + $data_menu + ']').addClass('megamenusecond-show');$currentelement.closest('li').parent().closest('li').find('.megamenusecond-new[data-menu=' + $data_menu + ']').find('li.level_4:first-child').addClass('activeli');//console.log('subchild-'+title);var subChildLevel_cat_id=$currentelement.closest('li').data("cat");var subChildLevel_taxnomy_type = $currentelement.closest('li').data("type");var ChildLevel_data_type= $(".mega-options > li.project_m.activeli").data("type");var ChildLevel_data_cat_id= $(".mega-options > li.project_m.activeli").data("cat_id");var parent_data_cat_id= $currentelement.closest('.themegamenu').data("main_cat_id");var parent_data_type= $currentelement.closest('.themegamenu').data("main_type");// checking 4th level menu /*** 4th level Objec code here **/// End getting parent data-menuif($('.megamenusecond.megamenusecond-new').length > 0){var subofSubChildLevel_cat_id = $('.megamenusecond[data-menu='+$data_menu+']').find('li.level_4.activeli').data('cat');var subofSubChildLevel_data_menu = $('.megamenusecond[data-menu='+$data_menu+']').find('li.level_4.activeli').data('menu');var subofSubChildLevel_taxnomy_type= $('.megamenusecond[data-menu='+$data_menu+']').find('li.level_4.activeli').data('type');var subofSubChildLevel_title = $('.megamenusecond[data-menu='+$data_menu+']').find('li.level_4.activeli>a').html();if(subofSubChildLevel_title!==''){var ajx_title=subofSubChildLevel_title;}else{var ajx_title=subChildLevel_title;}if(subofSubChildLevel_cat_id!=''){var data_obj= {'title':ajx_title,'subofSubChildLevel_cat_id':subofSubChildLevel_cat_id,'subofSubChildLevel_taxnomy_type':subofSubChildLevel_taxnomy_type,'subChildLevel_cat_id': subChildLevel_cat_id,'subChildLevel_taxnomy_type' :subChildLevel_taxnomy_type,'ChildLevel_data_type':ChildLevel_data_type,'ChildLevel_data_cat_id':ChildLevel_data_cat_id,'parent_data_cat_id':parent_data_cat_id,'parent_data_type':parent_data_type};}else{var data_obj= {'title':ajx_title,'subChildLevel_cat_id': subChildLevel_cat_id,'subChildLevel_taxnomy_type' :subChildLevel_taxnomy_type,'ChildLevel_data_type':ChildLevel_data_type,'ChildLevel_data_cat_id':ChildLevel_data_cat_id,'parent_data_cat_id':parent_data_cat_id,'parent_data_type':parent_data_type};}}else{var data_obj= {'title':subChildLevel_title,'subChildLevel_cat_id': subChildLevel_cat_id,'subChildLevel_taxnomy_type' :subChildLevel_taxnomy_type,'ChildLevel_data_type':ChildLevel_data_type,'ChildLevel_data_cat_id':ChildLevel_data_cat_id,'parent_data_cat_id':parent_data_cat_id,'parent_data_type':parent_data_type};} if( ajaxRequestProject != null ) {ajaxRequestProject.abort();ajaxRequestProject = null;}ajaxRequestProject = $.ajax({ type: 'POST', url: 'https://pharmaceutical-business-review.com/wp-admin/admin-ajax.php?action=mega_posts', dataType: "html", data: data_obj, beforeSend: function() {$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html('');},success: function(response) {$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html(response);},error: function(xhr) { // if error occured$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html("Error occured.please try again"); }});}//last child levelfunction get_lastchildlevelmenu(currentid){var $currentelement = $('#'+currentid);$('.menu-item-'+$('#'+currentid).closest('.themegamenu').attr('cid').split('-')[3]).removeClass('defaultajax-1');var $data_menu = $currentelement.closest('li').attr('data-menu'); var submenu = $data_menu.split('-'); var data_menu_class=submenu[0];var $ajax_data_menu = $currentelement.closest('li').attr('data-ajax'); var ajax_submenu = $ajax_data_menu.split('-'); var ajax_data_menu_class=ajax_submenu[0]+'-'+ajax_submenu[1];var ajaxreplaceContent = $('#'+currentid).closest('.themegamenu').data('megamenu')+'-articles';$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').empty();$('.megamenuthird').removeClass('megamenuthird-show');$('.megamenuthird[data-menu=' + $data_menu + ']').addClass('megamenuthird-show');$('li.level_4').removeClass('activeli');$currentelement.closest('li').addClass('activeli');var title = $currentelement.html();var subofSubChildLevel_cat_id=$currentelement.closest('li').data("cat");var subofSubChildLevel_taxnomy_type = $currentelement.closest('li').data("type");var subofSubChildLevel_title = $currentelement.closest('li').find('li.level_4.activeli>a').html();var subChildLevel_cat_id=$('.megamenusecond[data-menu='+ajax_data_menu_class+']').find('li.level_3.activeli').data('cat');var subChildLevel_data_menu=$('.megamenusecond[data-menu='+ajax_data_menu_class+']').find('li.level_3.activeli').data('menu');var subChildLevel_taxnomy_type = $('.megamenusecond[data-menu='+ajax_data_menu_class+']').find('li.level_3.activeli').data('type');var ChildLevel_data_type= $(".mega-options > li.project_m.activeli").data("type");var ChildLevel_data_cat_id= $(".mega-options > li.project_m.activeli").data("cat_id");var parent_data_cat_id= $currentelement.closest('.themegamenu').data("main_cat_id");var parent_data_type= $currentelement.closest('.themegamenu').data("main_type");var data_obj= {'title':title,'subofSubChildLevel_cat_id':subofSubChildLevel_cat_id,'subofSubChildLevel_taxnomy_type':subofSubChildLevel_taxnomy_type,'subChildLevel_cat_id': subChildLevel_cat_id,'subChildLevel_taxnomy_type' :subChildLevel_taxnomy_type,'ChildLevel_data_type':ChildLevel_data_type,'ChildLevel_data_cat_id':ChildLevel_data_cat_id,'parent_data_cat_id':parent_data_cat_id,'parent_data_type':parent_data_type};if( ajaxRequestProject != null ) {ajaxRequestProject.abort();ajaxRequestProject = null;}ajaxRequestProject = $.ajax({ type: 'POST', url: 'https://pharmaceutical-business-review.com/wp-admin/admin-ajax.php?action=mega_posts', dataType: "html", data:data_obj, beforeSend: function() {$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html('');},success: function(response) {$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html(response);},error: function(xhr) { // if error occured$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html("Error occured.please try again"); }});} $(document).ready(function(){//$('body').addClass('loaded');/********* End Third Level on over show/hide ****/$('.news-box-big').hover(function() {$(this).closest('.news').children('.big_title').toggleClass("bordertop");});$('.news-box-medium').hover(function() {$(this).closest('.medium_title').children('.tbt').toggleClass("bordertop");}); /********* Newsletter onclick events start here *******/ $(".header-cta a").click(function(e){ var $elem = $('.newsletter-box').position(); $('html,body').animate({ scrollTop: $(".newsletter-box").offset().top - 80}, 'fast'); }); /***** Newsletter onclick events End here *******/ /* Close guided tour */ $(".close-guided-tour").click(function(){$(".home_timeline").hide(); }); /* Close guided tour */ $(".close-guided-tour2").click(function(){ $(".timeline-tour2").hide(); }); /* $( ".fa-search" ).click(function() { $( 'body' ).toggleClass('search-open'); //$('.search-form').toggle(); }); $('.search-toggle').click(function () {$('.search-form').toggleClass('expanded');}); */ // Search toggle$('.navbar .search-toggle, .mobilesearch').click(function(e){e.preventDefault();$(this).parent().toggleClass('active').find('input[type="search"]').focus();});$('.search-submit').click(function(e){if( $(this).parent().find('.search-field').val() == '' ) {e.preventDefault();$(this).parent().parent().removeClass('active');}}); }); /* Reached newsletter */ $(function(){ $(document).scroll(function(){ if($(this).scrollTop() >= $('.email-capture').offset().top - 50) { $('body').addClass("email-capture-reached"); } else{ $('body').removeClass("email-capture-reached"); } if($(this).scrollTop() >= $('.timeline').offset().top - 50) { $('body').addClass("timeline-tour-open"); } else{ $('body').removeClass("timeline-tour-open"); } }); }); /****** Article page Share n/w ********/ $('.social-toggle').on('click', function() { $(this).next().toggleClass('open-menu'); }); /*** End Article page Share n/w ********/ /* Close guided tour */ $(".close-guided-tour2").click(function(){ $("body").addClass("timeline-closed"); }); /* End Timeline guided tour Track the news */ /* Reached related headline */ $(function(){ $(document).ready(function(){ $('body').addClass("headline-reached"); }); }); /* Reached start */ /*$(function(){ $(document).scroll(function(){ if($(this).scrollTop() >= $('#start').offset().top - 50) { $('body').addClass("start-reached"); } else{ $('body').removeClass("start-reached"); } }); });*/ /* Reached share-content */ $(function(){ $(document).scroll(function(){ if($(this).scrollTop() >= $('.share-content').offset().top - 50) { $('body').addClass("share-content-reached"); } else{ $('body').removeClass("share-content-reached"); } }); }); /* share copy-link section */ function myFunction() { var copyText = document.getElementById("copylink"); copyText.select(); document.execCommand("Copy"); } /* Reached first sidebar mpu */ $(function(){ $(document).scroll(function(){ if($(this).scrollTop() >= $('.mpu1').offset().top - 50) { $('body').addClass("reached-mpu1"); } else{ $('body').removeClass("reached-mpu1"); } }); }); /* Sticky sidebar banner */ /* $(function(){ $(document).scroll(function(){ if ($(window).width() > 1400) { if($(this).scrollTop() >= $('#sticky-mpu').offset().top - 250 ) { $('.sidebar').addClass("banner-fixed"); } else{ $('.sidebar').removeClass("banner-fixed"); } } }); });*/ // Select all links with hashes $('a[href*="#"]') // Remove links that don't actually link to anything .not('[href="#"]') .not('[href="#0"]') .click(function(event) { // On-page links if ( location.pathname.replace(/^//, '') == this.pathname.replace(/^//, '') && location.hostname == this.hostname ) { // Figure out element to scroll to var target = $(this.hash); target = target.length ? target : $('[name=' + this.hash.slice(1) + ']'); // Does a scroll target exist? if (target.length) { // Only prevent default if animation is actually gonna happen event.preventDefault(); $('html, body').animate({ scrollTop: target.offset().top }, 1000, function() { // Callback after animation // Must change focus! var $target = $(target); $target.focus(); if ($target.is(":focus")) { // Checking if the target was focused return false; } else { $target.attr('tabindex','-1'); // Adding tabindex for elements not focusable $target.focus(); // Set focus again }; }); } } }); /******** onclick share button in catgeory page ******/ $(".share-button").click(function(){ if($(this).parent('.open-share').length == 0){ $('.share').removeClass('open-share'); $(this).parent('.share').addClass("open-share"); }else{ $('.share').removeClass('open-share'); } }); /************* Mobile menu js *******/ function openNav() { document.getElementById("mobilemenu").style.width = "100%"; document.getElementById("mobilemenu").style.left = "0px"; } function closeNav() { document.getElementById("mobilemenu").style.width = "0"; } $( ".mobilemenuicon" ).click(function() { setTimeout(function(){ $( '.mobile-menu-cta' ).addClass("mobilectashow"); }, 500); }); $( ".closebtn" ).click(function() { $( '.mobile-menu-cta' ).removeClass("mobilectashow") }); /********** End mobile menu js *******/ /********* contractors Single page close Header**/ $(".close_section").click(function(){ $('.headersf').hide(1000); $('.headersf').addClass('section_closed'); $('.header-singleproduct').addClass('margin_top_added'); $('.small_header_sf').addClass('small_header_sf_display'); }); /******* End contractors Single page close Header**/ /*** My accout drop down menu */ $('.ctanav .dropdown-menu a').on('click', function() { window.location.href = $(this).attr('href'); }); /*** cookie-popup **/ $("#cookiepopup-continue").click(function(){ $.cookie("cookie_compelo", 'https://pharmaceutical-business-review.com'); $('.home_timeline').hide(); }); $(window).on("load",function(){ var data = $.cookie("cookie_compelo"); if(data){ $('.home_timeline').hide(); }else{ $('.home_timeline').show(); } }); $(".home_timeline .close").click(function(){ $.cookie("cookie_compelo", 'https://pharmaceutical-business-review.com'); $('.home_timeline').hide(); }); $(window).on("load",function(){ var data = $.cookie("cookie_compelo"); if(data){ $('.home_timeline').hide(); }else{ $('.home_timeline').show(); } }); /*** End cookie popup **/ /**** New add js code ***/ if ($(window).width() > 960) { // Initialization $(function(){ $('[data-scroll-speed]').moveIt(); }); } /* Sticky sidebar banner EVENT PAGE */ $(function(){ $(document).scroll(function(){ var scroll = $(window).scrollTop(); if (scroll >= 655) { $('.sticky-mpu-event').addClass("banner-fixed"); } else{ $('.sticky-mpu-event').removeClass("banner-fixed"); } }); }); //advertising page jQuery.fn.moveIt = function(){ var $window = jQuery(window); var instances = []; jQuery(this).each(function(){ instances.push(new moveItItem($(this))); }); window.addEventListener('scroll', function(){ var scrollTop = $window.scrollTop(); instances.forEach(function(inst){ inst.update(scrollTop); }); }, {passive: true}); } var moveItItem = function(el){ this.el = jQuery(el); this.speed = parseInt(this.el.attr('data-scroll-speed')); }; moveItItem.prototype.update = function(scrollTop){ this.el.css('transform', 'translateY(' + -(scrollTop / this.speed) + 'px)');};// InitializationjQuery(function(){jQuery('[data-scroll-speed]').moveIt();}); /**** end new add js code **/

Read more from the original source:
AgeX Therapeutics, ImStem Biotechnology sign non-binding letter of intent regarding investigational MSC candidate IMS001 for Covid-19 - Pharmaceutical...

The report presents an in-depth assessment of the Biotechnology Reagents Market including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents forecasts for Biotechnology Reagents investments from 2020 till 2026.

Global biotechnology reagents market is expected to rise from its initial estimated value of USD 65.82 billion in 2018 to an estimated value of USD 118.53 billion by 2026, registering a CAGR of 7.63% in the forecast period of 2019-2026.

Click the link to get a Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/11191577929/global-biotechnology-reagents-market-professional-survey-report-2019/inquiry?source=coleofduty&Mode=48

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Biotechnology Reagents Market: Agilent Technologies, Thermo Fisher Scientific, SGS, Shimadzu, Waters, Charles River Laboratories, Bioinformatics Solutions, Proteome Factory, Rapid Novor, Selvita

Biotechnology reagents are substances or compounds used to detect or synthesize another substance in order to give a reading test. These reagents are used in the field of research, genetics, molecular biology, diagnosis, immunology and bioscience. Biotechnology reagent consists of technologies such as cell culture, spectrometry, IVD, PCR, chromatography, expression and transfection, flow cytometer, and electrophoresis, and finds their application in various fields such as the immune phenotype, fluorescent microscopy, DNA analysis and cell cycle analysis.

This report segments on the basis of Types:

Life Science ReagentsAnalytical Reagents

Split On the basis of Applications:

Protein Synthesis and PurificationGene ExpressionDNA and RNA AnalysisDrug Testing

Inquire for Discount:

https://www.marketinsightsreports.com/reports/11191577929/global-biotechnology-reagents-market-professional-survey-report-2019/discount?source=coleofduty&Mode=48

Regional Analysis:

For comprehensive understanding of market dynamics, the global Biotechnology Reagents Market is analysed across key geographies namely: United States, China, Europe, Japan, South-east Asia, India and others. Each of these regions is analysed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Influence of the Biotechnology Reagents Market report:

-Comprehensive assessment of all opportunities and risk in the Biotechnology Reagents Market.

-Biotechnology Reagents Market recent innovations and major events.

-Detailed study of business strategies for growth of the Biotechnology Reagents Market-leading players.

-Conclusive study about the growth plot of Biotechnology Reagents Market for forthcoming years.

-In-depth understanding of Biotechnology Reagents Market-particular drivers, constraints and major micro markets.

-Favourable impression inside vital technological and market latest trends striking the Biotechnology Reagents Market.

The report has 150 tables and figures browse the report description and TOC:

https://www.marketinsightsreports.com/reports/11191577929/global-biotechnology-reagents-market-professional-survey-report-2019?source=coleofduty&Mode=48

What are the market factors that are explained in the report?

Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

Analytical Tools: The Global Biotechnology Reagents Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and investment return analysis have been used to analysed the growth of the key players operating in the market.

Finally, Biotechnology Reagents Market report is the believable source for gaining the Market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request and Market development rate and figure and so on. This report additionally Present new task SWOT examination, speculation attainability investigation, and venture return investigation.

Note: All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

We Also Offer Customization on report based on specific client Requirement:

Free country Level analysis for any 5 countries of your choice.

Free Competitive analysis of any 5 key market players.

Free 40 analyst hours to cover any other data point.

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected] | [emailprotected]

Visit link:
Biotechnology Reagents Market Analysis and Technology Advancement Outlook 2020 to 2025 - Cole of Duty

Thanks to its newly announced COVID-19 antibody therapy candidates, Vir Biotechnology's (NASDAQ:VIR) stock is still up more than 10% from the beginning of May and more than 180% from the start of the year.On top of its recent gains, there's reason to believe that Vir is positioned perfectly for continued growth.

While the company has a long way to go before it reaches profitability, between its low-risk pipeline programs for COVID-19 and a demonstrated competency for preclinical drug development for infectious disease, Vir's future seems bright.

Image source: Getty Images.

Vir's preclinical COVID-19 projects include two antibody therapies that it claims could temporary prevention and the treatment of coronavirus infections. VIR-7832 is both a prophylactic and a therapeutic, whereas VIR-7831 is only a therapeutic.

Because they are antibody therapies, Vir's candidates would be more effective at helping sick patients get better by reducing their viral load than it would be at preventing infections like a traditional vaccine might. In a nutshell, both of Vir's antibody programs could help patients to fight COVID-19 immediately by neutralizing viral particles in their bloodstream after they get a dose of the therapy. Then, once the patient's symptoms subside, the antibodies would remain in their system for several days or weeks, protecting them from re-infection. This process is key to both of Vir's COVID-19 antibody programs, but there's a bit more to the story.

Vir suspects that VIR-7832 may also function as a T-cell vaccine, training the immune system to react to future infections. This would mean that patients could be administered the antibody even if they don't expect to get sick. If Vir's hunch is correct, VIR-7832 would provide longer-lasting immunity than VIR-7831, and it might be a contender for mass production as a prophylactic.

The company's approach is uncontroversial from a scientific perspective, given that neutralizing antibodies from COVID-19 survivors have already been shown to combat the disease in vitro by numerous independent research teams and similar therapies were successfully used to treat human patients with SARS. Similarly, Vir's approach is front-run by ongoing clinical trials testing the efficacy of antibodies from recovered COVID-19 patients on improving disease outcomes in people who are currently ill.

The average vaccine in development is estimated to have only a 6% chance of proceeding all the way to approval and the market, but Vir's antibody products may fare better because they are adapted from natural antibodies known to be effective and safe. There's no guarantee of Vir's efforts ending in blockbuster revenue, but in the highly risky world of biotech, the prospects of these two COVID-19 projects are extremely favorable even from a conservative perspective.

However, given that the antibodies would be copies of naturally ocurring antibodies, it's uncertain whether intellectual property protection would be sufficient to prevent a competitor from creating very similar products. For most biotech companies, this would be a dealbreaker, as it would effectively prevent the ability to recoup development costs with a period of exclusive production rights. But not for Vir. By bucking the traditional wisdom regarding exclusivity and drug development, Vir has a real chance of entering the market sooner than competitors at a time when demand for its product would be enormously high.

That isn't to say that Vir is an unambitious company because it is moving forward with safer programs. In contrast to its two antibody therapy programs, Vir's VIR-2703 program is riskier because it uses a scientific approach which hasn't been tested in humans for the purpose of infectious disease. Rather than acting to neutralize viral particles directly like an antibody might, VIR-2703 relies on small chunks of genetic information called silencing RNAs (siRNAs) which disrupt regions of the viral genome.

Counting on this program to succeed would be a mistake. Most large pharmaceutical companies gave up trying to develop siRNA therapies in the mid-2010s after nearly a decade of failures, and the only siRNA therapy approved by the FDA isn't for an infectious disease.

On the other hand, early favorable clinical results from VIR-2703 should not be interpreted as a reason to buy the company's stock. Stumbles stemming from a lack of a proof of concept in human patients further down the pipeline could easily erase any gains. Either way, Vir's drug development pipeline looks more like a risk-balanced portfolio than a selection of technological and scientific gambles like so many other biotechs.

If Vir brings one of its COVID-19 programs to market, it'll be one more addition to the company's impressive roster of therapies and prophylactics for viral diseases. Aside from its three unique COVID-19 programs, Vir's pipeline includes a handful of other projects intended to treat or prevent illnesses caused by hepatitis B, influenza, tuberculosis, and even HIV. Importantly, all but two of these pipeline projects are in the preclinical phase, so the company's clinical acumen is far from proven.

In terms of advanced programs, the closest Vir has to offer is its VIR-2218 therapy for hepatitis B, which it suspects may be curative for most patients. If Vir brings a curative therapy to market, the company may have trouble maintaining its revenue over the long term because a cure shrinks the pool of eligible patients. As the hepatitis B therapeutics market is only worth around $2.6 billion, it's possible that Vir's hepatitis B therapy would meet the same fate as the low-earning hepatitis C therapy produced by Gilead Sciences (NASDAQ:GILD)But, with 257 million people worldwide living with hepatitis B compared to only 71 million living with hepatitis C, it's less likely that Vir will experience the same difficulties. Importantly, Vir isn't letting Gilead's experience stop them from moving forward with a curative therapy candidate. Even if the long-term profitability of VIR-2218 is in jeopardy of being a victim of its own success, Vir is willing to take a chance rather than stick to a safer opportunity.

In summary, Vir's COVID-19 pipeline has two antibody programs that have a better than average chance of passing through clinical trials.Elsewhere, the company's technology platform appears formidable, but its clinical pipeline is still in its infancy, despite a bevy of compelling seedlings.

Given the level of public need for COVID-19 treatments and vaccines, it's likely that if Vir's COVID-19 programs look promising once they hit the clinic in the summer, they'll be expedited through clinical trials. This means that the company's minimal past experience in clinical operations and clinical development will be of little use, so it's likely to need to lean heavily on larger collaborators like Biogen, GlaxoSmithKline, and Alnylam Pharmaceuticals.

It's easy to envision a future where Vir gets acquired by one of these collaborators if its trials have positive outcomes. In the meantime, progress by Vir's major competitors like Novavax and behemoth vaccine producers like Merck is unlikely to diminish the company's upward trajectory, as competing products would be targeted at preventing COVID-19 rather than both treating and preventing it.

Image Source: YCharts

As the market grows to recognize Vir as a rising contender in the COVID-19 therapeutic market, public interest in the company will explode, to the benefit of its shareholders. I'd recommend buying Vir shares now, to maximize the benefit of successive boosts to the company's stock price as its COVID-19 candidates pass through each phase of clinical trials. Holding onto Vir for a few years will maximize the gains, but don't discount the probability of near-term gains either.

More here:
Vir Biotechnology Is Bucking The Biotech COVID-19 Trends, And Stands To Win - Motley Fool

Dublin, June 02, 2020 (GLOBE NEWSWIRE) -- The "Biotechnology Reagents - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.

The Global Biotechnology Reagents market accounted for $69.21 billion in 2018 and is expected to reach $163.19 billion by 2027 growing at a CAGR of 10.0% during the forecast period. Rising number of biotechnology firms and growth in biopharmaceuticals are the major factors propelling the market growth. However, high cost of reagents is hampering the market growth.

Biotechnology reagents are the substances used to detect or synthesize another substance so as to provide a test reading. The biotechnological reagents play an important role in the age of rapid research, discovery, and publication in the industry and academic research purposes.

Based on the technology, the analytical segment is going to have a lucrative growth during the forecast period as chromatography technique of analytical technology is mostly used in drug discovery to validate the specificity, sensitivity, and purity of drugs and deliver precise outcomes to validate characters. By geography, North America is going to have a lucrative growth during the forecast period owing to high investments, new product developments, presence of favorable government policies and sophisticated healthcare infrastructure.

Some of the key players profiled in the Biotechnology Reagents Market include Siemens Healthineers, Quality Biological Inc., Merck Millipore, PerkinElmer, Meridian Bioscience, Promega Corporation, Lonza Group AG, BioMrieux, GE Healthcare, Bio-Rad Laboratories, Life Technologies, Beckman Coulter, Agilent Technologies, Abbott Laboratories and Becton Dickinson.

What our report offers:

Key Topics Covered:

1 Executive Summary

2 Preface2.1 Abstract 2.2 Stake Holders 2.3 Research Scope 2.4 Research Methodology2.4.1 Data Mining2.4.2 Data Analysis2.4.3 Data Validation2.4.4 Research Approach2.5 Research Sources 2.5.1 Primary Research Sources 2.5.2 Secondary Research Sources 2.5.3 Assumptions

3 Market Trend Analysis3.1 Introduction 3.2 Drivers 3.3 Restraints 3.4 Opportunities 3.5 Threats 3.6 Technology Analysis 3.7 Application Analysis 3.8 End User Analysis 3.9 Emerging Markets 3.10 Impact of Covid-19

4 Porters Five Force Analysis

5 Global Biotechnology Reagents Market, By Technology5.1 Introduction 5.2 Life Science 5.2.1 Polymerase Chain Reaction 5.2.1.1 Master Mixes 5.2.1.2 Kits5.2.1.3 Individual Reagent 5.2.2 Cell/Tissue Culture5.2.2.1 Sera5.2.2.2 Media and Regents 5.2.3 In-Vitro Diagnostics5.2.3.1 Microbiology Culture 5.2.3.2 Hematology 5.2.3.3 Immunoassay 5.2.3.4 Clinical Chemistry 5.2.3.5 Molecular Diagnostics 5.2.4 Expression and Transfection 5.3 Analytical 5.3.1 Chromatography5.3.1.1 Super Critical Fluid Chromatography5.3.1.2 Liquid Chromatography 5.3.1.3 Ion Chromatography 5.3.1.4 Gas Chromatography 5.3.1.5 Reagents Type 5.3.1.5.1 Solvent 5.3.1.5.2 Chemical 5.3.1.5.3 Adsorbents 5.3.2 Mass Spectrometry5.3.2.1 Proteomics 5.3.2.2 Drug Discovery 5.3.2.3 Clinical Testing 5.3.2.4 Genomics5.3.3 Electrophoresis5.3.3.1 Gel5.3.3.2 Dye5.3.3.3 Buffer5.3.4 Flow Cytometry5.3.4.1 Cell-based Flow Cytometry 5.3.4.2 Bead-based Flow Cytometry

6 Global Biotechnology Reagents Market, By Application6.1 Introduction 6.2 Protein Synthesis and Purification 6.3 Immunophenotyping 6.4 Gene Expression 6.5 Fluorescent Microscopy6.6 Drug testing 6.7 DNA and RNA analysis6.8 Cell Cycle Analysis

7 Global Biotechnology Reagents Market, By End User7.1 Introduction 7.2 Research Institutes 7.3 Pharmaceuticals 7.4 Diagnostic Centers 7.5 Biotech Companies

8 Global Biotechnology Reagents Market, By Geography8.1 Introduction 8.2 North America 8.2.1 US 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 UK 8.3.3 Italy 8.3.4 France 8.3.5 Spain 8.3.6 Rest of Europe8.4 Asia Pacific 8.4.1 Japan 8.4.2 China 8.4.3 India 8.4.4 Australia 8.4.5 New Zealand8.4.6 South Korea8.4.7 Rest of Asia Pacific8.5 South America 8.5.1 Argentina 8.5.2 Brazil 8.5.3 Chile 8.5.4 Rest of South America 8.6 Middle East & Africa 8.6.1 Saudi Arabia8.6.2 UAE 8.6.3 Qatar 8.6.4 South Africa8.6.5 Rest of Middle East & Africa

9 Key Developments9.1 Agreements, Partnerships, Collaborations and Joint Ventures9.2 Acquisitions & Mergers9.3 New Product Launch 9.4 Expansions 9.5 Other Key Strategies

10 Company Profiling10.1 Siemens Healthineers10.2 Quality Biological Inc.10.3 Merck Millipore 10.4 PerkinElmer 10.5 Meridian Bioscience 10.6 Promega Corporation10.7 Lonza Group AG 10.8 BioMrieux 10.9 GE Healthcare 10.10 Bio-Rad Laboratories10.11 Life Technologies 10.12 Beckman Coulter 10.13 Agilent Technologies 10.14 Abbott Laboratories 10.15 Becton Dickinson

For more information about this report visit https://www.researchandmarkets.com/r/y9konb

Story continues

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read more:
Outlook on the Worldwide Biotechnology Reagents Industry to 2027 - Agreements, Partnerships and Collaborations & Joint Ventures - Yahoo Finance

Global Media, Sera and Reagents in Biotechnology Market: Trends Estimates High Demand by 2027

The Media, Sera and Reagents in Biotechnology Market 2020 report includes the market strategy, market orientation, expert opinion and knowledgeable information. The Media, Sera and Reagents in Biotechnology Industry Report is an in-depth study analyzing the current state of the Media, Sera and Reagents in Biotechnology Market. It provides a brief overview of the market focusing on definitions, classifications, product specifications, manufacturing processes, cost structures, market segmentation, end-use applications and industry chain analysis. The study on Media, Sera and Reagents in Biotechnology Market provides analysis of market covering the industry trends, recent developments in the market and competitive landscape.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Media, Sera and Reagents in Biotechnology market. All findings and data on the global Media, Sera and Reagents in Biotechnology market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Media, Sera and Reagents in Biotechnology market available in different regions and countries.

The final report will add the analysis of the Impact of Covid-19 in this report Media, Sera and Reagents in Biotechnology industry.

Some of The Companies Competing in The Media, Sera and Reagents in Biotechnology Market are: Athena Environmental Science, Inc., Becton, Dickinson, CellGenix, GE Healthcare, Lonza, Thermo Fisher Scientific, Inc., and

Get a Sample Copy of the [emailprotected] https://www.reportsandmarkets.com/sample-request/covid-19-impact-on-global-media-sera-and-reagents-in-biotechnology-market-size-status-and-forecast-2020-2026?utm_source=coleofduty&utm_medium=24

The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used Porters five techniques for analyzing the Media, Sera and Reagents in Biotechnology Market; it also offers the examination of the global market. To make the report more potent and easy to understand, it consists of info graphics and diagrams. Furthermore, it has different policies and improvement plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

Global Media, Sera and Reagents in Biotechnology Market Research Report 2020 carries in-depth case studies on the various countries which are involved in the Media, Sera and Reagents in Biotechnology market. The report is segmented according to usage wherever applicable and the report offers all this information for all major countries and associations. It offers an analysis of the technical barriers, other issues, and cost-effectiveness affecting the market. Important contents analyzed and discussed in the report include market size, operation situation, and current & future development trends of the market, market segments, business development, and consumption tendencies. Moreover, the report includes the list of major companies/competitors and their competition data that helps the user to determine their current position in the market and take corrective measures to maintain or increase their share holds.

What questions does the Media, Sera and Reagents in Biotechnology market report answer pertaining to the regional reach of the industry?

The report claims to split the regional scope of the Media, Sera and Reagents in Biotechnology market into North America, Europe, Asia-Pacific, South America & Middle East and Africa. Which among these regions has been touted to amass the largest market share over the anticipated duration

How do the sales figures look at present how does the sales scenario look for the future?

Considering the present scenario, how much revenue will each region attain by the end of the forecast period?

How much is the market share that each of these regions has accumulated presently

How much is the growth rate that each topography will depict over the predicted timeline

A short overview of the Media, Sera and Reagents in Biotechnology market scope:

Global market remuneration

Overall projected growth rate

Industry trends

Competitive scope

Product range

Application landscape

Supplier analysis

Marketing channel trends Now and later

Sales channel evaluation

Market Competition Trend

Market Concentration Rate

Reasons to Read this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

Chapter 1:Media, Sera and Reagents in Biotechnology Market Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3:Media, Sera and Reagents in Biotechnology Market Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Media, Sera and Reagents in Biotechnology Market Effect Factors Analysis

Chapter 12: GlobalMedia, Sera and Reagents in Biotechnology Market Forecast to 2027

Get Complete Report @ https://www.reportsandmarkets.com/sample-request/covid-19-impact-on-global-media-sera-and-reagents-in-biotechnology-market-size-status-and-forecast-2020-2026?utm_source=coleofduty&utm_medium=24

About Us:

Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Are you mastering your market? Do you know what the market potential is for your product, who the market players are and what the growth forecast is? We offer standard global, regional or country specific market research studies for almost every market you can imagine.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Follow this link:
Research on Media, Sera and Reagents in Biotechnology Market (impact of COVID-19) with Top Players: Athena Environmental Science, Inc., Becton,...

The report is one of the most comprehensive and accurate research studies on the Nanoparticles in Biotechnology and Pharmaceuticals Market. Sheds light on market competition, segmentation, regional growth, and dynamics, such as drivers, constraints, trends, and opportunities. It provides validated and revalidated market figures, which include market size, CAGR, market share, revenue, gross margin, production, and consumption. It offers absolute dollar opportunity analysis, manufacturing cost analysis, Porters five-force analysis, qualitative and quantitative analysis, and PESTLE analysis to provide a complete understanding of the Nanoparticles in Biotechnology and Pharmaceuticals market. It is prepared with the use of the best techniques and tools for primary and secondary research.

Request Sample Copy of this Report @ https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=FLS&utm_medium=003

Top 10 Companies in the Nanoparticles in Biotechnology and Pharmaceuticals Market Research Report:

The regional analysis provided in the report helps to familiarize yourself with the growth opportunities available in different regions and countries around the world. Provides market share, consumption, production, income, and other important geographic market research. The competitive analysis includes the company profile of the main players based on recent developments, revenue, gross margin and other key factors. The report offers useful recommendations for players to secure a solid position in the Nanoparticles in Biotechnology and Pharmaceuticals market. It comes as a powerful set of guidelines to prepare for unforeseen challenges and ensure healthy growth in the Nanoparticles in Biotechnology and Pharmaceuticals market.

Table of Contents

Market Overview: Offers a broad product scope and Nanoparticles in Biotechnology and Pharmaceuticals market overview followed by a look at the segmentation study provided in the report. For product segments, it offers production and growth rate comparisons followed by production market shares, and for application segments, it offers a deep consumption comparison. For regional segments, it provides comparisons of market size and growth rate for the 2013-2025 review period. It also includes the perspective of the size of the global market, taking into account production and income.

Manufacturers Competition Here, manufacturers production, earnings, and average price are studied alongside their stocks. In addition, manufacturers products and manufacturing base distribution are discussed in this section, followed by competitive situations and trends.

Production by region: This section highlights global capacity, production and income and their market shares by region, followed by analysis of prices and gross margin. Each regional market studied in the report is analyzed in terms of production, growth rate, income, price, production, capacity and gross margin.

Manufacturing Cost Analysis: In this part of the report, analysts have focused on the analysis of key raw materials, the proportion of the manufacturing cost structure, and the analysis of manufacturing processes. Under the analysis of key raw materials, they discussed the key raw materials, their price trend, their suppliers and their market concentration rate. Under the proportion of the manufacturing cost structure, they have concentrated on raw materials and labor costs.

Global Market Forecast: The global market forecast includes a detailed perspective of capacity, production, revenue, growth rate, and price trend. This section also provides a forecast of all the regional markets studied in the report based on production, income, consumption and price.

Ask For Discounts @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=FLS&utm_medium=003

Influential factors

The main questions our analysts have addressed

What policies and regulations will have a major impact on the global market?What are the current and future opportunities in the global market?What will be the size of the global market in the next five years?What are the important dynamics of the market?

Research Methodology

Competitive scene

The main objectives of the report

Customized Research Report Using Corporate Email Id @https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=FLS&utm_medium=003

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Read more here:
Nanoparticles in Biotechnology and Pharmaceuticals Market Key Players, SWOT Analysis, Dynamics, Drivers, Key Indicators and Forecast to 2026 - Farmers...

Here's a roundup of top developments in the biotech space over the last 24 hours:

(Biotech Stocks Hitting 52-week Highs June 1)

(Biotech Stocks Hitting 52-week Lows June 1)

Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) said the FDA approved its Tecentriq in combination with Avastin for the treatment of people with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

Allena Pharmaceuticals Inc (NASDAQ: ALNA) shares were surging ahead of the company's presentation at the Jefferies Virtual Healthcare Conference. The shares were higher in Monday's regular session, reacting to an initiation by H.C. Wainwright with a Buy rating and $10 price target.

Analyst Edward White said the biopharma is an "undervalued enzyme therapeutic company."

Following a 31.55% jump to $2.21 in Monday's regular session, Allena shares were rallying by 35.29% to $2.99 in Tuesday's premarket session.

Esperion Therapeutics Inc (NASDAQ: ESPR) shares came under pressure after a federal district court accorded class action status to a lawsuit filed on behalf of investors, alleging the company issued misleading statements about its non-statin cholesterol-lowering drug Nexletol in a bid to artificially inflate thestock price.

The stock fell after it was evident the drug did not have a clear path to regulatory approval, the lawsuit alleged.

The stock slid 3.07% to $40.77 in after-hours trading.

Related Link:The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight

Pfizer Inc. (NYSE: PFE) announced the establishment of the Pfizer Breakthrough Growth Initiative, through which the company said itwill invest up to $500 million in biotechnology companies to help provide funding and access to its scientific expertise to ensure continuity of the biotechnology companies' most promising clinical development programs.

Sumitovant Biopharma said its affiliate Myovant Sciences Ltd (NYSE: MYOV) has submitted an NDA for the once-daily relugolix combo tablet, comprising relugolix 40 mg, estradiol 1mg and norethindrone acetate 0.5 mg, for the treatment of women with heavy menstrual bleeding associated with uterine fibroids.

The stock was trading 0.95% higher at $17.09 in the premarket session.

Sanofi SA (NASDAQ: SNY) said the European Commission has approved its Sarclisain combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.

Aytu Bioscience Inc (NASDAQ: AYTU) said it has retired $15 million debt assumed in connection with its previously announced acquisition of Cerecor Inc's(NASDAQ: CERC) Commercial Portfolio.

Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) said a revised offer from Melinta received in response to another revised offer from anothersuitor,AcelRx Pharmaceuticals Inc (NASDAQ: ACRX), has been deemed a superior offer by its board.

Melinta and AcelRx have been engaged in a bidding war to lap up Tetraphase, with both companies sweetening their respective bids a few times.

The revised AcelRx offer received May 27 called for exchanging each unit ofTetraphase stock for $0.5872 in cash and 0.7409AcelRx shares, representing $1.70 in upfront per share value, and one CVR, entitling the holders to receive potential payments of up to $16 million in cash upon the achievement of certain future Xerava net sales milestones starting in 2021.

Melinta's most recent bid offered $39 million in cash,plus an additional $16 million in cash potentially payable under CVR to be issued in the proposed acquisition.

In premarket trading Tuesday, Tetraphase gained 6.9% to $2.48, while AcelRx shares were surging higher by 6.3% to $1.35.

OraSure Technologies, Inc. (NASDAQ: OSUR) said it has commenced an underwritten public offering of 8 million shares of its common stock.

The stock slipped 4.32% to $13.51 in after-hours trading.

Adaptimmune priced its underwritten public offering of 20.5 million shares of its ADSs at $11 eachfor gross proceeds of $225.5 million. The company expects the offering to close on or about June 4.

Kaleido Biosciences Inc (NASDAQ: KLDO) priced its underwritten public offering of 4.75 million shares of its common stock at $7.50 per share. The company expects to raise gross proceeds of $35.6 million from the offering. All the shares are being offered by the company. The offering is expected to close June 4.

The stock was trading 2.87% higher at $8.24 in the premarket session.

Allogene Therapeutics Inc (NASDAQ: ALLO) priced its underwritten public offering of 11.702 million shares at $47 per share for gross proceeds of $550 million.The offering is expected to close on or about June 4.

The stock fell 0.57% to $48.66 in after-hours trading.

Guardant Health Inc (NASDAQ: GH) announced the commencement of a proposed underwritten public offering of 10 million shares of its common stock, of which 3 million shares are being offered by Guardant Health and 7 million by SoftBank Investment.

The stock was up 0.1% at $48.99 premarket.

G1 Therapeutics Inc (NASDAQ: GTHX) said it has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $100 million. The company plans to use the proceeds to fund commercialization and further development of trilaciclib, its first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy.

Intellia Therapeutics Inc (NASDAQ: NTLA) said it has commenced an underwritten public offering of $75 million of shares of its common stock. All of the shares in the proposed offering are to be sold by Intellia.

Intellia shares were trading 0.91% higher at $20.73 premarket Tuesday.

Related Link: Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

See the original post here:
The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs - Benzinga

Global Biotechnology Market Report is a professional and in-depth research report on the worlds major regional market. The Biotechnology industry2020 by Industry Demand, Business Strategy & Emerging Trends by Leading Players. The Global pandemic of COVID19/CORONA Virus calls for redefining of business strategies. This Biotechnology Market report includes the impact analysis necessary for the same.

Download the Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6321901/biotechnology-market

Top Players Listed in the Biotechnology Market Report areJohnson & Johnson, Roche, Pfizer, Merck, Sanofi, AstraZeneca, Gilead, CELGENE CORPORATION, Biogen, Amgen, Abbott, Novo Nordisk, Novartis, Lonza, .

Biotechnologymarket report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, the impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market Segmentations: Global Biotechnology market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer.

Based on type, report split into DNA Sequencing, Nanobiotechnology, Tissue engineering and Regeneration, Fermentation, Cell Based Assay, PCR Technology, Chromatography Market, Others.

Based on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Health, Food & Agriculture, Natural Resources & Environment, Industrial Processing, Bioinformatics.

Get Exclusive Sample of Report on Biotechnology market is available at https://inforgrowth.com/sample-request/6321901/biotechnology-market

The report introduces Biotechnology basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis. Insightful predictions for the Biotechnology Market for the coming few years have also been included in the report.

In the end, Biotechnologyreport provides details of competitive developments such as expansions, agreements, new product launches, and acquisitions in the market for forecasting, regional demand, and supply factor, investment, market dynamics including technical scenario, consumer behavior, and end-use industry trends and dynamics, capacity, spending were taken into consideration.

Important Key questions answered in Biotechnologymarket report:

Get Special Discount Up To 50%, https://inforgrowth.com/discount/6321901/biotechnology-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

Read the original:
COVID-19 Update: Global Biotechnology Market is Expected to Grow at a Healthy CAGR with Top players: Johnson & Johnson, Roche, Pfizer, Merck,...

The 60 rating InvestorsObserver gives to Cara Therapeutics Inc (CARA) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 52 percent of stocks in the Biotechnology industry, CARAs 60 overall rating means the stock scores better than 60 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 60 means the stock is more attractive than 60 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Cara Therapeutics Inc (CARA) stock is trading at $15.57 as of 3:36 PM on Thursday, Jun 4, a loss of -$0.50, or -3.11% from the previous closing price of $16.07. The stock has traded between $15.57 and $16.25 so far today. Volume today is low. So far 360,678 shares have traded compared to average volume of 569,619 shares.

To screen for more stocks like CARA click here.

Follow this link:
Is Cara Therapeutics Inc (CARA) a Winner in the Biotechnology Industry? - InvestorsObserver

The market research report published by QYResearch is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Pharmaceutical & Biotechnology Environmental Monitoring market. It informs readers about key trends and opportunities in the global Pharmaceutical & Biotechnology Environmental Monitoring market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Pharmaceutical & Biotechnology Environmental Monitoring market.

Key companies operating in the global Pharmaceutical & Biotechnology Environmental Monitoring market include , Danaher Corporation, Thermo Fisher Scientific, Merck KGaA, Eurofins Sinensis, Lonza, Biomerieux, VAI, Cosasco, RMONI, Amphenol Advanced Sensors, Vaisala Pharmaceutical & Biotechnology Environmental Monitoring

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1436318/global-pharmaceutical-amp-biotechnology-environmental-monitoring-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Pharmaceutical & Biotechnology Environmental Monitoring market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Pharmaceutical & Biotechnology Environmental Monitoring Market Segment By Type:

, Monitoring Equipment, Media, Software, Microbiology Services Pharmaceutical & Biotechnology Environmental Monitoring

Global Pharmaceutical & Biotechnology Environmental Monitoring Market Segment By Application:

, Pharmaceutical Industry, Biotechnology Industry, Academic & Research Institutes

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Pharmaceutical & Biotechnology Environmental Monitoring market.

Key companies operating in the global Pharmaceutical & Biotechnology Environmental Monitoring market include , Danaher Corporation, Thermo Fisher Scientific, Merck KGaA, Eurofins Sinensis, Lonza, Biomerieux, VAI, Cosasco, RMONI, Amphenol Advanced Sensors, Vaisala Pharmaceutical & Biotechnology Environmental Monitoring

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1436318/global-pharmaceutical-amp-biotechnology-environmental-monitoring-market

TOC

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Pharmaceutical & Biotechnology Environmental Monitoring Revenue1.4 Market Analysis by Type 1.4.1 Global Pharmaceutical & Biotechnology Environmental Monitoring Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Monitoring Equipment 1.4.3 Media 1.4.4 Software 1.4.5 Microbiology Services1.5 Market by Application 1.5.1 Global Pharmaceutical & Biotechnology Environmental Monitoring Market Share by Application: 2020 VS 2026 1.5.2 Pharmaceutical Industry 1.5.3 Biotechnology Industry 1.5.4 Academic & Research Institutes1.6 Coronavirus Disease 2019 (Covid-19): Pharmaceutical & Biotechnology Environmental Monitoring Industry Impact 1.6.1 How the Covid-19 is Affecting the Pharmaceutical & Biotechnology Environmental Monitoring Industry 1.6.1.1 Pharmaceutical & Biotechnology Environmental Monitoring Business Impact Assessment Covid-19 1.6.1.2 Supply Chain Challenges 1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products 1.6.2 Market Trends and Pharmaceutical & Biotechnology Environmental Monitoring Potential Opportunities in the COVID-19 Landscape 1.6.3 Measures / Proposal against Covid-19 1.6.3.1 Government Measures to Combat Covid-19 Impact 1.6.3.2 Proposal for Pharmaceutical & Biotechnology Environmental Monitoring Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Global Growth Trends by Regions2.1 Pharmaceutical & Biotechnology Environmental Monitoring Market Perspective (2015-2026)2.2 Pharmaceutical & Biotechnology Environmental Monitoring Growth Trends by Regions 2.2.1 Pharmaceutical & Biotechnology Environmental Monitoring Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Pharmaceutical & Biotechnology Environmental Monitoring Historic Market Share by Regions (2015-2020) 2.2.3 Pharmaceutical & Biotechnology Environmental Monitoring Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Pharmaceutical & Biotechnology Environmental Monitoring Market Growth Strategy 2.3.6 Primary Interviews with Key Pharmaceutical & Biotechnology Environmental Monitoring Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Pharmaceutical & Biotechnology Environmental Monitoring Players by Market Size 3.1.1 Global Top Pharmaceutical & Biotechnology Environmental Monitoring Players by Revenue (2015-2020) 3.1.2 Global Pharmaceutical & Biotechnology Environmental Monitoring Revenue Market Share by Players (2015-2020) 3.1.3 Global Pharmaceutical & Biotechnology Environmental Monitoring Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Pharmaceutical & Biotechnology Environmental Monitoring Market Concentration Ratio 3.2.1 Global Pharmaceutical & Biotechnology Environmental Monitoring Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Pharmaceutical & Biotechnology Environmental Monitoring Revenue in 20193.3 Pharmaceutical & Biotechnology Environmental Monitoring Key Players Head office and Area Served3.4 Key Players Pharmaceutical & Biotechnology Environmental Monitoring Product Solution and Service3.5 Date of Enter into Pharmaceutical & Biotechnology Environmental Monitoring Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Pharmaceutical & Biotechnology Environmental Monitoring Historic Market Size by Type (2015-2020)4.2 Global Pharmaceutical & Biotechnology Environmental Monitoring Forecasted Market Size by Type (2021-2026) 5 Pharmaceutical & Biotechnology Environmental Monitoring Breakdown Data by Application (2015-2026)5.1 Global Pharmaceutical & Biotechnology Environmental Monitoring Market Size by Application (2015-2020)5.2 Global Pharmaceutical & Biotechnology Environmental Monitoring Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Pharmaceutical & Biotechnology Environmental Monitoring Market Size (2015-2020)6.2 Pharmaceutical & Biotechnology Environmental Monitoring Key Players in North America (2019-2020)6.3 North America Pharmaceutical & Biotechnology Environmental Monitoring Market Size by Type (2015-2020)6.4 North America Pharmaceutical & Biotechnology Environmental Monitoring Market Size by Application (2015-2020) 7 Europe7.1 Europe Pharmaceutical & Biotechnology Environmental Monitoring Market Size (2015-2020)7.2 Pharmaceutical & Biotechnology Environmental Monitoring Key Players in Europe (2019-2020)7.3 Europe Pharmaceutical & Biotechnology Environmental Monitoring Market Size by Type (2015-2020)7.4 Europe Pharmaceutical & Biotechnology Environmental Monitoring Market Size by Application (2015-2020) 8 China8.1 China Pharmaceutical & Biotechnology Environmental Monitoring Market Size (2015-2020)8.2 Pharmaceutical & Biotechnology Environmental Monitoring Key Players in China (2019-2020)8.3 China Pharmaceutical & Biotechnology Environmental Monitoring Market Size by Type (2015-2020)8.4 China Pharmaceutical & Biotechnology Environmental Monitoring Market Size by Application (2015-2020) 9 Japan9.1 Japan Pharmaceutical & Biotechnology Environmental Monitoring Market Size (2015-2020)9.2 Pharmaceutical & Biotechnology Environmental Monitoring Key Players in Japan (2019-2020)9.3 Japan Pharmaceutical & Biotechnology Environmental Monitoring Market Size by Type (2015-2020)9.4 Japan Pharmaceutical & Biotechnology Environmental Monitoring Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Pharmaceutical & Biotechnology Environmental Monitoring Market Size (2015-2020)10.2 Pharmaceutical & Biotechnology Environmental Monitoring Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Pharmaceutical & Biotechnology Environmental Monitoring Market Size by Type (2015-2020)10.4 Southeast Asia Pharmaceutical & Biotechnology Environmental Monitoring Market Size by Application (2015-2020) 11 India11.1 India Pharmaceutical & Biotechnology Environmental Monitoring Market Size (2015-2020)11.2 Pharmaceutical & Biotechnology Environmental Monitoring Key Players in India (2019-2020)11.3 India Pharmaceutical & Biotechnology Environmental Monitoring Market Size by Type (2015-2020)11.4 India Pharmaceutical & Biotechnology Environmental Monitoring Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Pharmaceutical & Biotechnology Environmental Monitoring Market Size (2015-2020)12.2 Pharmaceutical & Biotechnology Environmental Monitoring Key Players in Central & South America (2019-2020)12.3 Central & South America Pharmaceutical & Biotechnology Environmental Monitoring Market Size by Type (2015-2020)12.4 Central & South America Pharmaceutical & Biotechnology Environmental Monitoring Market Size by Application (2015-2020) 13 Key Players Profiles13.1 Danaher Corporation 13.1.1 Danaher Corporation Company Details 13.1.2 Danaher Corporation Business Overview and Its Total Revenue 13.1.3 Danaher Corporation Pharmaceutical & Biotechnology Environmental Monitoring Introduction 13.1.4 Danaher Corporation Revenue in Pharmaceutical & Biotechnology Environmental Monitoring Business (2015-2020)) 13.1.5 Danaher Corporation Recent Development13.2 Thermo Fisher Scientific 13.2.1 Thermo Fisher Scientific Company Details 13.2.2 Thermo Fisher Scientific Business Overview and Its Total Revenue 13.2.3 Thermo Fisher Scientific Pharmaceutical & Biotechnology Environmental Monitoring Introduction 13.2.4 Thermo Fisher Scientific Revenue in Pharmaceutical & Biotechnology Environmental Monitoring Business (2015-2020) 13.2.5 Thermo Fisher Scientific Recent Development13.3 Merck KGaA 13.3.1 Merck KGaA Company Details 13.3.2 Merck KGaA Business Overview and Its Total Revenue 13.3.3 Merck KGaA Pharmaceutical & Biotechnology Environmental Monitoring Introduction 13.3.4 Merck KGaA Revenue in Pharmaceutical & Biotechnology Environmental Monitoring Business (2015-2020) 13.3.5 Merck KGaA Recent Development13.4 Eurofins Sinensis 13.4.1 Eurofins Sinensis Company Details 13.4.2 Eurofins Sinensis Business Overview and Its Total Revenue 13.4.3 Eurofins Sinensis Pharmaceutical & Biotechnology Environmental Monitoring Introduction 13.4.4 Eurofins Sinensis Revenue in Pharmaceutical & Biotechnology Environmental Monitoring Business (2015-2020) 13.4.5 Eurofins Sinensis Recent Development13.5 Lonza 13.5.1 Lonza Company Details 13.5.2 Lonza Business Overview and Its Total Revenue 13.5.3 Lonza Pharmaceutical & Biotechnology Environmental Monitoring Introduction 13.5.4 Lonza Revenue in Pharmaceutical & Biotechnology Environmental Monitoring Business (2015-2020) 13.5.5 Lonza Recent Development13.6 Biomerieux 13.6.1 Biomerieux Company Details 13.6.2 Biomerieux Business Overview and Its Total Revenue 13.6.3 Biomerieux Pharmaceutical & Biotechnology Environmental Monitoring Introduction 13.6.4 Biomerieux Revenue in Pharmaceutical & Biotechnology Environmental Monitoring Business (2015-2020) 13.6.5 Biomerieux Recent Development13.7 VAI 13.7.1 VAI Company Details 13.7.2 VAI Business Overview and Its Total Revenue 13.7.3 VAI Pharmaceutical & Biotechnology Environmental Monitoring Introduction 13.7.4 VAI Revenue in Pharmaceutical & Biotechnology Environmental Monitoring Business (2015-2020) 13.7.5 VAI Recent Development13.8 Cosasco 13.8.1 Cosasco Company Details 13.8.2 Cosasco Business Overview and Its Total Revenue 13.8.3 Cosasco Pharmaceutical & Biotechnology Environmental Monitoring Introduction 13.8.4 Cosasco Revenue in Pharmaceutical & Biotechnology Environmental Monitoring Business (2015-2020) 13.8.5 Cosasco Recent Development13.9 RMONI 13.9.1 RMONI Company Details 13.9.2 RMONI Business Overview and Its Total Revenue 13.9.3 RMONI Pharmaceutical & Biotechnology Environmental Monitoring Introduction 13.9.4 RMONI Revenue in Pharmaceutical & Biotechnology Environmental Monitoring Business (2015-2020) 13.9.5 RMONI Recent Development13.10 Amphenol Advanced Sensors 13.10.1 Amphenol Advanced Sensors Company Details 13.10.2 Amphenol Advanced Sensors Business Overview and Its Total Revenue 13.10.3 Amphenol Advanced Sensors Pharmaceutical & Biotechnology Environmental Monitoring Introduction 13.10.4 Amphenol Advanced Sensors Revenue in Pharmaceutical & Biotechnology Environmental Monitoring Business (2015-2020) 13.10.5 Amphenol Advanced Sensors Recent Development13.11 Vaisala 10.11.1 Vaisala Company Details 10.11.2 Vaisala Business Overview and Its Total Revenue 10.11.3 Vaisala Pharmaceutical & Biotechnology Environmental Monitoring Introduction 10.11.4 Vaisala Revenue in Pharmaceutical & Biotechnology Environmental Monitoring Business (2015-2020) 10.11.5 Vaisala Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read more from the original source:
Pharmaceutical & Biotechnology Environmental Monitoring Market 2020 Industry Analysis, Size, Share, Trends, Market Demand, Growth, Opportunities...

Agricultural Biotechnology Market is analyzed with industry experts in mind to maximize return on investment by providing clear information needed for informed business decisions. This research will help both established and new entrants to identify and analyze market needs, market size and competition. It explains the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities and the threats faced by key players.

Sample Copy of This Report:https://www.quincemarketinsights.com/request-sample-67083

A 360 degree outline of the competitive scenario of the Global Agricultural BiotechnologyMarket is presented by QuinceMarketInsights. It has a massive data allied to the recent product and technological developments in the markets.

It has a wide-ranging analysis of the impact of these advancements on the markets future growth, wide-ranging analysis of these extensions on the markets future growth. The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.

Key players: KWS SAAT SE & Co. KGaA, ChemChina, Limagrain, Nufarm, Marrone Bio Innovations, Performance Plants Inc., Corteva, ADAMA Ltd, MITSUI & CO., LTD, Evogene Ltd., Valent BioSciences LLC, and Bayer AG.

Reasons for buying this report:

By Application (Vaccine, Flower Culturing, Biofuels)

By Organism (Plants, Animals, Microbes)

Get Discount on This Report: https://www.quincemarketinsights.com/request-discount-67083

A detailed outline of the Global Agricultural BiotechnologyMarket includes a comprehensive analysis of different verticals of businesses. North America, Europe, Asia Pacific, Middle East & Africa, and South America have been considered for the studies on the basis of several terminologies.

This is anticipated to drive the Global Agricultural BiotechnologyMarket over the forecast period. This research report covers the market landscape and its progress prospects in the near future. After studying key companies, the report focuses on the new entrants contributing to the growth of the market. Most companies in the Global Agricultural BiotechnologyMarket are currently adopting new technological trends in the market.

Finally, the researchers throw light on different ways to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the Global Agricultural BiotechnologyMarket. The feasibility of the new report is also measured in this research report.

If You Have Any Query, Ask Our Experts:https://www.quincemarketinsights.com/enquiry-before-buying-67083

Table of Contents:

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 121 364 6144

Email:sales@quincemarketinsights.com

Web:https://www.quincemarketinsights.com

Read the rest here:
Impact of Covid-19 on Agricultural Biotechnology Market Outlook, Revenue, Trends and Forecasts Research Report 2020-2028 - Azizsalon News

SAN FRANCISCO, May 28, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the upcoming Goldman Sachs 41st Annual Global Healthcare Conference.

Goldman Sachs 41st Annual Global Healthcare Conference

Date: June 11, 2020Fireside Chat Time: 3:50 PM E.T. Location: Virtual

A live audio webcast of the fireside chat will be available through the Investors & Media section of UNITYs website. An archived replay will be available for 90 days following the event.

About UNITYUNITY is developing therapeutics to extend healthspan with an initial focus on cellular senescence. UNITY believes that the accumulation of senescent cells is a fundamental mechanism of aging and a driver of many common age-related diseases. Cellular senescence is a natural biological state in which a cell permanently halts division. As senescent cells accumulate with age, they begin secreting inflammatory factors, proteases, fibrotic factors, and growth factors, that disturb the tissue micro-environment. This collection of secreted proteins is referred to as the Senescence Associated Secretory Phenotype, or SASP. UNITY is developing senolytic medicines to eliminate senescent cells and thereby stop the production of the SASP, which UNITY believes addresses a root cause of age-related diseases. By stopping the production of the SASP at it source, UNITY believes senolytic medicines could slow, halt, or reverse diseases such as osteoarthritis and age-related eye diseases. More information is available atwww.unitybiotechnology.comor follow us onTwitter.

Investors Endurance AdvisorsMike Zanonimzanoni@enduranceadvisors.com

Media Canale CommunicationsJason Sparkjason@canalecomm.com

Read this article:
UNITY Biotechnology to Participate in the Goldman Sachs 41st Annual Global Healthcare Conference - GlobeNewswire

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Food Biotechnology market.

Trusted Business Insights presents an updated and Latest Study on Food Biotechnology Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Food Biotechnology market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Food Biotechnology Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Food Biotechnology MarketIndustry / Sector Trends

Global Food Biotechnology Market size was valued at over USD 23 billion in 2018 and is anticipated to witness over 10% CAGR up to 2025.

Increasing penetration of advanced technologies to develop new products by modifying plants, animals, and microorganisms genes to provide innovative solutions is driving the market growth. Shifting trends towards healthy lifestyles accompanied by a rise in processed food demand has urged the F&B manufacturers to improve the nutritional content in their products, thereby generating new growth opportunities for the biotech-based industry players. Further, there is a requirement to enhance the shelf life and taste of food by the use of encapsulation techniques and other ingredients.

Strong growth in functional food & beverages and dietary supplements industry is resulting in increased competitiveness, thus propelling the food biotechnology market revenue. As per CCI, the global nutraceutical market including functional F&B and dietary supplements is projected to reach USD 241 billion in 2019, observing around 7% CAGR from 2014 to 2019. Factors such as robust expansion of food industry and low-cost biotech services particular in developing countries has escalated the adoption of services.

Stringent government regulations to enhance product quality and transparency are among the foremost aspects attributing to food biotech solutions. Also, modifications in labeling regulations asking for a declaration of GMOs, allergens, and nutritional content is surging the industry share. Further, consumer-driven movements such as clean label has urged food manufacturers to improve the quality by using natural ingredients instead of artificial constituents.

Changes in climatic conditions over the years has resulted in increased production of genetically modified (GM) crops or ingredients through the use of biotech services. This provides plants with improved resistance to diseases, insecticides, and herbicides, as well as extending the shelf life of the produce. However, growth in the organic food industry can hamper the demand for GM crops, thus affecting the food biotechnology industry share.

Market Segmentation, Outlook & Regional Insights: Food Biotechnology Market

Food Biotechnology Market, By Type

Transgenic segment dominates the global market accounting for over 75% share in 2018. Increasing demand for genetically modified crops to enhance productivity in low producing or harsh climatic conditions will drive segment growth. According to ISAAA, the global utilized area for biotech crops increased from 148 million hectares in 2010 to 190 million hectares in 2017. Countries including the U.S., Brazil, Argentina, Canada, and India holds over 90% of the total area under GM crop cultivation. Farmers shifting from conventional seeds to bio-seeds to improve their profit margins will escalate the market growth.

Germany Food Biotechnology Market Size, By Type, 2018 (USD Million)

Food Biotechnology Market, By Application

Global food biotechnology market through animal segment holds over 34% share in 2018. Increasing necessity to enhance milk production in dairy cattle with growing demand will propel industry expansion. Robust growth in meat consumption such as processed meat accompanied by increasing consumer awareness on nutritional benefits will drive the biotech applications. As per FAO, global meat production is projected to increase, reach around 48MT by 2025. Further, testing services for developing products to suit the human dietary requirements will drive market development.

Global food biotechnology market through plants is projected to account for over USD 22 billion in 2025. The key growth factors include an increase in the development of GM crops with pesticide resistance and abiotic stress tolerance to increase the yield. Reduction in the arable land area will further shift the preference towards biotechnological products. Enhanced focus on innovation of new food ingredients will surge the business revenues. Strong application outlook of biotech solutions to produce high-quality crops and reduce the health risk will augment business expansion.

Food Biotechnology Market, By Region

North America market is anticipated to cross USD 12 billion by 2025. High investments on technological advancements coupled with high consumer spending on nutritious products will augment the industry share. The U.S. is the largest producer of genetically modified crops with 75 million hectares area for biotech crops. Further, the presence of large multinational corporations, increasing private and government R&D investments, supported by favourable government policies will fuel the market growth. Further, positive application outlook of genetically modified yeast in developing new alcoholic beverages will support regional growth.

Asia Pacific Food Biotechnology Market, By Country, 2018 & 2025, (USD Million)

Asia Pacific food biotechnology market is projected to witness over 11% CAGR from 2019 to 2025. Countries including China, India, and Japan together dominate the regional market share. The demand for dietary supplements is increasing due to a shifting trend towards healthy lifestyles, thus increasing the demand for nutritional ingredients. Also, product innovations supported by the rise in per capita income will drive the biotech solutions on health foods. Further, the necessity to augment the agricultural output owing to the rise in population, along with severe climatic variations will drive the biotechnology industry share.

Key Players, Recent Developments & Sector Viewpoints: Food Biotechnology Market

Global market is competitive due to the presence of large multinationals and regional players. Key industry participants in market include BASF SE, Bayer CropScience AG, AquaBounty Technologies, ABS Global, Dow AgroSciences LLC, Arcadia Biosciences, Camson Bio Technologies Ltd, BDF Ingredients Zuchem, and Monsanto. Product development, geographic expansion, mergers, acquisitions, and collaborations are among the key strategies observed in the industry. For instance, in 2017, Bayer and Ginkgo Bioworks announced to launch a company to developing new technologies for engineering the plant microbiome.

Industry Viewpoint

Food biotechnology market is driven by the requirement for improving the productivity and quality of the edible items by altering genes. Growth in the food & beverages industry, increasing population, rising disposable incomes, and health awareness are among the major factors creating a long-term positive impact. Biotechnological product innovations among food manufacturers will provide lucrative opportunities for business growth. North America and Europe are among the early adopters of biotech services, however developing regions are also expected to implement advanced solutions in food industry. The penetration rate is high in Asia Pacific owing to strong R&D investments and the necessity for increasing the food productivity and animal milk output

Key Insights Covered: Exhaustive Food Biotechnology Market1. Market size (sales, revenue and growth rate) of Food Biotechnology industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Food Biotechnology industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Food Biotechnology industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Food Biotechnology industry.

Research Methodology: Food Biotechnology Market

Quick Read Table of Contents of this Report @ Food Biotechnology Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read the original post:
Food Biotechnology Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 - Cole of Duty

A report, added to the extensive database of verified Market Research titled Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 by Manufacturer, Region, Type and Application, Forecast up to 2026, is intended to highlight first-hand documentation of all the best implementations in the industry. The report contains an in-depth analysis of current and future market trends, segmentation, industrial opportunities and the future market scenario, taking into account the forecast years 2020 to 2026. It contains extremely important details on the key players in the Nanoparticles in Biotechnology and Pharmaceuticals market as well as growth-oriented practices, that they normally use. The report examines a number of growth drivers and limiting factors. The key forecast information by region, type and application with sales and revenue from 2020 to 2026 is included in this report.

Request Sample Copy of this Report @ https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=WCS&utm_medium=001

Top 10 Companies in the Nanoparticles in Biotechnology and Pharmaceuticals Market Research Report:

Competitive landscape:

The report examines the major players, including the profiles of the major players in the market with a significant global and / or regional presence, combined with their information such as related companies, downstream buyers, upstream suppliers, market position, historical background and top competitors based on the Sales with sales contact information.

Regional Description:

The Nanoparticles in Biotechnology and Pharmaceuticals market was analyzed and a proper survey of the market was carried out based on all regions of the world. The regions listed in the report include: North America (United States, Canada, and Mexico), Europe (Germany, France, United Kingdom, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina , Colombia etc.), Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa). All these regions have been studied in detail and the prevailing trends and different possibilities are also mentioned in the market report.

Sales and sales broken down by application:

Sales and sales divided by type:

In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the Nanoparticles in Biotechnology and Pharmaceuticals market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=WCS&utm_medium=001

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model

5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution

6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical

7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=WCS&utm_medium=001

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

More here:
Impact of Covid-19 Outbreak on Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Trends, Growth Opportunities, Demand, Application, Top...

New Delhi: The Department of Biotechnology has taken several proactive measures to streamline the biosafety regulation and to facilitate researchers and industries which are undertaking research and development in Recombinant DNA Technology and Hazardous Microorganisms.

1. Operationalization of Indian Biosafety Knowledge Portal. The Indian Knowledge Biosafety Portal launched in May, 2019 was made fully operationalized and now the Department is receiving all new applications through online portal only. This has made the whole process transparent and time bound.

2. Notification of Revised Simplified Guidelines on Import, Export and Exchange of GE Organisms and Product Thereof for R&D Purpose: The Department issued the Revised Guidelines in January, 2020 in which Institutional Biosafety Committee have been delegated authority to take decisions on applications of import export and exchange of GE organisms and product thereof for R&D purpose for RG1 and RG2 items.

3. Facilitation of Research and Development on COVID-19: Considering the emerging situations of spread of Coronavirus and with the understanding on requirement of rapid research and development for COVI-19, the Department has proactively taken several steps to facilitate researchers and industries involved in research on COVID19. DBT has issued following guidelines, orders and checklist on COVID 19:

Rapid Response Regulatory Framework for COVID-19 to deal with application for development of vaccines, diagnostics, prophylactics and therapeutics has been notified on 20.03.2020DBT notified Interim Guidance Document on Laboratory Biosafety to Handle COVID-19 Specimens on 08.04.2020.IBSCs are allowed to conduct their meeting through video conferencing up to 30thJune, 2020.Rapid response regulatory framework for development of recombinant DNA COVID 19 vaccine was issued on 26.05.2020.

Read more:
A Rapid Response Regulatory enabling mechanism facilitated by Department of Biotechnology for COVID 19 - India Education Diary